Document is current

Article History

Received: 26 June 2019

Accepted: 20 September 2019

First Online: 30 October 2019

Ethics approval and consent to participate

: This study was performed according to the Declaration of Helsinki and received appropriate ethical approval. All patients provided written informed consent via a form signed at either the Pre-screening or Screening visit.

: Not applicable.

: IHB, DAL, CC, MV-B, and PWJ are employees of GSK and hold stocks and shares in GSK. IPN and MLW were employees of GSK at the time of the study. LT is a contingent worker on assignment at GSK. FM has received research grants for participating in multicentre trials for AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Novartis, and has received unrestricted research grants and personal fees from Boehringer Ingelheim, Grifols, and Novartis. LB has received honoraria for giving a lecture or attending an advisory board for Airsonett, ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Meda, Novartis and Teva. EMK has served on advisory boards, speaker panels or received travel reimbursement from for Amphastar, AstraZeneca, Boehringer Ingelheim, GSK, Mylan, Novartis, Pearl, Sunovion, Teva, and Theravance and has received consulting fees from Cipia and GSK. CFV has received grants from AstraZeneca, Boehringer Ingelheim, GSK, Grifols, Novartis, Bayer-Schering, MSD, and Pfizer, and has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, GSK, Grifols, Menarini, Mundipharma, Novartis, and Teva. ELLIPTA and DISKUS are owned by/licensed to the GSK group of companies.